ClinicalTrials.gg
CompletedNCT03529877Updated Oct 7, 2022

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

A Phase 1/2 interventional study of allo-APZ2-EB in Recessive Dystrophic Epidermolysis Bullosa, sponsored by RHEACELL GmbH & Co. KG. Completed at 6 sites in 5 countries. Open to participants aged 0 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-07.

Sponsored by RHEACELL GmbH & Co. KG · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
0 Years to 55 Years
Sex
All
01

Study summary

The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with recessive dystrophic epidermolysis bullosa (RDEB).

Read the detailed description

This is an interventional, single arm, non-randomized, open label, phase I/IIa clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-EB in patients with RDEB.

Patients will undergo treatment with the IMP (three repeated intravenous applications) and will be followed up for efficacy for 12 weeks. To assess long-term safety of allo-APZ2-EB one follow-up visit at Month 12 and one follow-up visit at Month 24 post IMP applications is included.

Determination of the EB linked symptoms and quality of life will be assessed by using the EBDASI score, the iscorEB, the change in pain and itch perception, and patient's quality of life in EB. The wound healing process will be documented by photography.

02

Conditions studied

  • Recessive Dystrophic Epidermolysis Bullosa

Keywords

  • Epidermolysis Bullosa
  • Epidermolysis Bullosa Dystrophica
  • Skin Abnormalities
  • Congenital Abnormalities
  • Skin Diseases, Genetic
  • Somatic Cell Therapy
  • Mesenchymal Stem Cells
  • ABCB5
  • Allogeneic
03

In context

Epidermolysis Bullosa Dystrophica

79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.

This study's enrollment of 16 is above the median of 9 across 56 interventional studies indexed under Epidermolysis Bullosa Dystrophica.

Browse Epidermolysis Bullosa Dystrophica studies →

Lead sponsor

RHEACELL GmbH & Co. KG is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged between 0 and ≤55 years;

Staggered design for patient enrollment:

  1. at least 3 adult patients (safety assessment 2 weeks after last treatment of third patient),
  2. at least 3 patients ≥12 to \<18 years (safety assessment 2 weeks after first treatment of third patient),
  3. at least 3 patients ≥5 to \<12 years (safety assessment 2 weeks after first treatment of third patient), and
  4. at least 3 patients ≥12 months to \<5 years;
  5. patients 0 to \<12 months (only in the UK);
  1. Diagnosed with RDEB (combined diagnosis by genotype assessment [mutation analysis] and correlating phenotype assessment [wound assessment]), patients must have a negative immunofluorescence test result on salt-split skin against proteins of the basement membrane at Visit 1 (existing test results will be accepted);
  1. Patient is eligible to participate in this clinical trial based on general health condition at the investigator's discretion;

US only:

Patient is eligible to participate in this clinical trial based on general health condition assessed by specific lab values (Hematology: >1000/mm3 and count >150,000/mcL; Coagulation: PT and \<2x the for age; Hepatic: and ALT \<2x the upper limit of normal for age; Renal: Creatinine \<2x the upper limit of normal for age; Pulmonary: Oxygen saturation >92% on room air and without supplemental oxygen requirement);

  1. Patient/legal representative understands the nature of the procedure and are providing written prior to any clinical trial procedure;
  1. Women of must have a negative urine pregnancy test at Visit 1;
  1. Women of childbearing potential and their partner must be willing to use highly effective methods during the course of the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Tumor diseases or history of tumor disease;
  2. Known positive result for 1 and/or 2;
  3. Any known allergies to components of the IMP;
  4. Evidence of any other medical conditions (such as psychiatric illness or active infection) based on physical examination, or laboratory findings that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment; at investigators discretion;
  5. History of prior thrombosis or patients at risk for thrombosis;
  6. or unstable concurrent disease or other clinical (based upon investigator's judgment);
  7. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;
  8. Pregnant or lactating women;
  9. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
  10. Previous participation in this clinical trial (except for screening failures due to an exclusion criterion);
  11. Known abuse of alcohol, drugs, or medicinal products;
  12. Employees of the sponsor, or employees or relatives of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    allo-APZ2-EB

    intravenous infusion, three doses of allo-APZ2-EB (2 x 10\^6 cells/kg)

    Biological: allo-APZ2-EB

Interventions

  • Biologicalallo-APZ2-EB

    intravenous infusion of allo-APZ2-EB

    Also known as: allogeneic ABCB5-positive mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing

    EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score

    Time frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing (last observation carried forward [LOCF])

  2. Assessment of adverse event (AE) occurrence

    All AEs occurring during the clinical trial will be registered, documented and evaluated.

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)

    EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score

    Time frame: between baseline and week 12 post baseline (without LOCF)

  2. Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing

    iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score

    Time frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing (LOCF);

  3. Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)

    iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score

    Time frame: between baseline and week 12 post baseline (without LOCF)

  4. Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)

    EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score

    Time frame: between baseline and day 17 post baseline

  5. Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)

    iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score

    Time frame: between baseline and day 17 post baseline

  6. Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)

    EBDASI: epidermolysis bullosa disease activity and scarring index; measured in percentage change to baseline score

    Time frame: between baseline and day 35 post baseline

  7. Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)

    iscorEB: instrument for scoring clinical outcome of research for epidermolysis bullosa; measured in percentage change to baseline score

    Time frame: between baseline and day 35 post baseline

  8. Inflammation (measured by panel of inflammation markers)

    A panel of inflammation markers will be measured and evaluated.

    Time frame: between baseline and day 17, day 35 and week 12 post baseline

  9. Pain assessment as per NRS

    Pain assessment as per numerical rating scale (NRS) will be evaluated.

    Time frame: between baseline and day 17, day 35 and week 12 post baseline

  10. Itch assessment as per NRS

    Itch assessment as per numerical rating scale (NRS) will be evaluated.

    Time frame: between baseline and day 17, day 35 and week 12 post baseline

  11. Differences in patient's quality of life in EB

    Assessment of quality of life data using an EB-specific quality of life questionnaire

    Time frame: between baseline and day 17, day 35 and week 12 post baseline

  12. Physical examination until Week 12;

    A full physical examination will be performed and abnormal physical examination results will be evaluated and reported as AEs.

    Time frame: At Screening, baseline, day 17, day 35 and week 12

  13. Vital signs: Body temperature until Week 12;

    Body temperature will be evaluated at Screening, baseline, day 17, day 35 and week 12

    Time frame: At Screening, baseline, day 17, day 35 and week 12

  14. Vital signs: Blood pressure until Week 12;

    Blood pressure will be evaluated at Screening, baseline, day 17, day 35 and week 12

    Time frame: At Screening, baseline, day 17, day 35 and week 12

  15. Vital signs: Heart rate until Week 12;

    Heart rate will be evaluated at Screening, baseline, day 17, day 35 and week 12

    Time frame: At Screening, baseline, day 17, day 35 and week 12

  16. Overall survival at month 24

    Time frame: month 24 post baseline

07

Study locations

6 sites
  • University of Minnesota, Masonic Cancer Center and Medical Center
    Minneapolis, Minnesota 55455, United States
  • EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU)
    Salzburg, 5020, Austria
  • Hôpital Saint-Louis; Département de dermatologie
    Paris, 75010, France
  • Department of Dermatology, Medical Center-University of Freiburg
    Freiburg, 79104, Germany
  • King's College London; St John's Institute of Dermatology;
    London, SE1 9RT, United Kingdom
  • Great Ormond Street Hospital; Dermatology Department
    London, WC1N 3JH, United Kingdom
08

References and documents

Publications

  • Kiritsi D, Dieter K, Niebergall-Roth E, Fluhr S, Daniele C, Esterlechner J, Sadeghi S, Ballikaya S, Erdinger L, Schauer F, Gewert S, Laimer M, Bauer JW, Hovnanian A, Zambruno G, El Hachem M, Bourrat E, Papanikolaou M, Petrof G, Kitzmuller S, Ebens CL, Frank MH, Frank NY, Ganss C, Martinez AE, McGrath JA, Tolar J, Kluth MA. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight. 2021 Nov 22;6(22):e151922. doi: 10.1172/jci.insight.151922. PubMed 34665781 ↗
  • Kerstan A, Niebergall-Roth E, Esterlechner J, Schroder HM, Gasser M, Waaga-Gasser AM, Goebeler M, Rak K, Schrufer P, Endres S, Hagenbusch P, Kraft K, Dieter K, Ballikaya S, Stemler N, Sadeghi S, Tappenbeck N, Murphy GF, Orgill DP, Frank NY, Ganss C, Scharffetter-Kochanek K, Frank MH, Kluth MA. Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data. Cytotherapy. 2021 Feb;23(2):165-175. doi: 10.1016/j.jcyt.2020.08.012. Epub 2020 Oct 1. PubMed 33011075 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Nov 2021, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2018
First posted
May 18, 2018
StartActual
Feb 16, 2019
Primary completionActual
Nov 26, 2021
CompletionActual
Nov 26, 2021
Last update
Oct 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03529877
Lead sponsor
RHEACELL GmbH & Co. KG
Collaborators
FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Ticeba GmbH
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Feb 16, 2019
Primary completion
Nov 26, 2021
Completion
Nov 26, 2021
Last update
Oct 7, 2022

Study contacts

Jakub Tolar, MD, PhD
principal investigator · University of Minnesota, Masonic Cancer Center and Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion